甘李药业涨2.01%，成交额2.42亿元，主力资金净流入1126.85万元

Core Viewpoint - 甘李药业 has shown positive stock performance and financial growth, indicating a strong position in the biopharmaceutical industry, particularly in the production of insulin analogs and related products [1][2]. Financial Performance - As of September 30, 2025, 甘李药业 achieved a revenue of 30.47 billion yuan, representing a year-on-year growth of 35.73% [2]. - The net profit attributable to shareholders for the same period was 8.18 billion yuan, reflecting a year-on-year increase of 61.32% [2]. - The company has distributed a total of 16.12 billion yuan in dividends since its A-share listing, with 10.18 billion yuan distributed over the past three years [3]. Stock Market Activity - On January 14, 甘李药业's stock price increased by 2.01%, reaching 71.51 yuan per share, with a trading volume of 2.42 billion yuan and a turnover rate of 0.61% [1]. - The stock has risen by 5.05% year-to-date, with a 0.03% increase over the last five trading days, a 6.64% increase over the last 20 days, and a 2.79% increase over the last 60 days [1]. Shareholder Information - The number of shareholders as of September 30, 2025, was 94,700, an increase of 22.53% from the previous period [2]. - The average number of circulating shares per shareholder was 5,889, a decrease of 17.81% from the previous period [2]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 8.0042 million shares, an increase of 494,300 shares from the previous period [3].